Standard 30 Gram Kayexalate Dose
The standard 30 gram dose of Kayexalate (sodium polystyrene sulfonate) is administered either as a single oral dose once daily or as a rectal enema (30-50 g) every 6 hours. 1
Dosing Regimens
According to FDA labeling, the standard dosing options for 30 g of Kayexalate are 1:
Oral Administration:
- 30 g orally once daily (equivalent to two 15 g doses)
- Part of the total daily dose range of 15-60 g, typically given as 15 g doses 1-4 times daily
- Each 15 g dose equals approximately four level teaspoons
Rectal Administration:
- 30-50 g as a retention enema every 6 hours
- Average adult rectal dose range
Clinical Evidence for 30 g Dosing
The 30 g oral dose once daily was specifically studied in the only randomized, double-blind, placebo-controlled trial of sodium polystyrene sulfonate 2. In this 7-day study of 33 outpatients with CKD and mild hyperkalemia (K+ 5.0-5.9 mEq/L), 30 g once daily reduced serum potassium by 1.25 mEq/L compared to 0.21 mEq/L with placebo (mean difference -1.04 mEq/L; P<0.001) 3.
Dose-Response Considerations
While 30 g is a standard dose, retrospective data suggests dose-dependent effects 4:
- 15 g oral: 0.39 mEq/L reduction
- 30 g oral: 0.69 mEq/L reduction
- 60 g oral: 0.91 mEq/L reduction
- 30 g rectal: only 0.22 mEq/L reduction
The 30 g oral dose represents a middle-ground option that provides meaningful potassium reduction while minimizing the substantial sodium load (1500 mg per 15 g dose) 2.
Critical Safety Warnings
Given the serious mortality and morbidity risks associated with sodium polystyrene sulfonate, strongly consider newer potassium binders (patiromer or sodium zirconium cyclosilicate) as first-line therapy instead 2. Sodium polystyrene sulfonate has been associated with 2:
- Intestinal ischemia and colonic necrosis (fatal cases reported)
- 33% overall mortality rate in some reports
- Doubled risk of hospitalization for serious GI adverse events
- Persistent tissue damage even after discontinuation 5
The evidence supporting SPS efficacy is limited to one small 7-day trial, while safety concerns are substantial and well-documented 2.
Important Caveats
- Onset of action is variable (hours to days), making this inappropriate for emergency hyperkalemia treatment 1
- Contains 20,000 mg sorbitol per 15 g dose when formulated with sorbitol; concomitant sorbitol use increases necrosis risk 2
- Avoid chronic use due to GI toxicity risk 6
- Separate other oral medications by at least 3 hours due to nonselective binding 1
- Monitor for hypomagnesemia and hypocalcemia due to nonselective cation binding 2